Ref.: VT 47 850

PROTEQFLU 10X1DS

Influenza

Pour voir le prix et/ou acheter ce produit, est indispensable d'être enregistré et validé en tant que vétérinaire agréé.
Si vous êtés déjà inscrit, connectez-vous à GirovetPro

Imprimir ficha del producto

Ajouter à la liste de souhaitsSupprimer de la liste de souhaits

Description

PHARMACEUTICAL FORM
Injectable suspension.

SPECIES
Horses.

Indications

Active immunization of horses 4 months of age or older against equine influenza for the reduction of clinical signs and viral excretion after infection.

- Start of immunity: 14 days after the primary vaccination.
- Duration of immunity induced by the vaccine schedule: 5 months after the primary vaccination and 1 year after the third vaccination.

Dose / Application / Administration

Route of administration:
Intramuscular.
Dosage:
- First vaccine schedule - Vaccination against equine influenza:
Administer one dose (1ml of ProteqFlu), by intramuscular injection, preferably in the neck, according to the following vaccination schedule:

Primary vaccination: first injection from 5 – 6 months, second injection 4 – 6 weeks later.
Booster injection: 5 months after the primary vaccination, and then annual boosters.

- Second vaccine schedule - Vaccination against equine influenza and tetanus:
Administer one dose (1ml) by intramuscular injection, preferably in the neck, according to the following vaccination schedule:

Primary vaccination with ProteqFlu-Te: first injection from 5 – 6 months, second injection 4 – 6 weeks later.
Booster injection: 5 months after the primary vaccination with ProteqFlu-Te. Followed by: or against tetanus: injection of 1 dose with a maximum interval of 2 years with ProteqFlu-Te. / Or against equine influenza: injection of 1 dose every year, alternatively with ProteqFlu or ProteqFlu-Te, respecting a maximum interval of 2 years for the tetanus component.

It can be used during pregnancy and lactation.

Composition

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1ml contains:

Active substance:
Recombinant canaripox virus Influenza A/eq/Ohio/03 [H3N8] (vCP2242): ≥ 5,3 log10 DIIF50*
Recombinant canaripox virus Influenza A/eq/Richmond/1/07 [H3N8] (vCP3011): ≥ 5,3 log10 DIIF50*
*vCP content checked by DIIF50 global (infectious dose 50 % by immunofluorescence) and qPCR ratio between vCP.

Adjuvant:
Carbomer: 4mg

Presentation

10 vials of 1ml

Laboratory

BOEHRINGER

Téléchargements

Information complète sur Proteqflu
FICHE TECHNIQUE